Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05234203 · ClinicalTrials.gov registry record · NA

The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age

A NA study of Aging and Inflammation, sponsored by Big Bold Health, PBC.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05234203 is a NA study of Aging and Inflammation that has completed, run by Big Bold Health, PBC. The registered enrollment target is 50 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05234203, a NA study of Aging and Inflammation, has completed, sponsored by Big Bold Health, PBC.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.

Interventions

  • DIETARY_SUPPLEMENT HTB Rejuvenate

Study Locations (1)

Washington

  • Big Bold Health PBC - Bainbridge Island

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-03-25
Est. Completion 2022-10-07
Phase NA

Sponsor

Big Bold Health, PBC

1 total trials

What the Registry Record Tells You About NCT05234203

The ClinicalTrials.gov registry entry for NCT05234203 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The listed sponsor is Big Bold Health, PBC, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which HTB Rejuvenate is the first listed.

NCT05234203 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT05234203 about?

NCT05234203 is a clinical study titled "The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age". This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.

What is the current status of trial NCT05234203?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-03-25. Estimated completion is 2022-10-07.

What conditions does trial NCT05234203 study?

This clinical trial studies the following conditions: Aging, Inflammation, Immunity Disorders.

What interventions are being tested in trial NCT05234203?

The interventions under investigation include: HTB Rejuvenate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05234203?

This trial is sponsored by Big Bold Health, PBC, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05234203 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.